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THE USAGE OF MESENCHYMAL STEM CELLS IN THE TREATMENT OF TYPE 1 
DIABETES MELLITUS 
ANDREW SCHULZ 
ABSTRACT 
 Type 1 Diabetes mellitus is a metabolic disorder characterized by an 
autoimmune attack against the insulin producing Beta-cells of the pancreas.  Also 
known as insulin-dependent diabetes, patients must receive exogenous injections of 
insulin in order to maintain glycemic homeostasis.  The necessity of monitoring 
one’s own blood glucose levels and self-administering insulin is a tedious routine for 
type 1 diabetics, and this standard treatment option fails to treat any of the 
underlying causes of the disease.   According to van Belle et al, the prevalence of 
diabetes is rising worldwide amongst all age-groups, from 2.8% in 2000 to an 
estimated 4.4% by 2030, thus the need to find a more curative treatment approach 
is eminent.  In the emerging field of regenerative medicine, mesenchymal stem cells 
have been identified as a possible therapeutic tool to replace damaged parenchymal 
tissue.  Along with their ability to modulate the local microenvironment, the 
introduction of properly differentiated mesenchymal stem cells into patients with 
Type 1 diabetes may provide a treatment option that helps supplement the lost islet 
cells without provoking an immune response.  Preliminary clinical trials have shown 
that stem cell therapy decreases the amount of exogenous insulin required daily, 
decreases fasting glucose levels, decreases amount of glycated hemoglobin and 
increases C-peptide levels.  These four indicators of diabetic control suggest that 
  v 
mesenchymal stem cells are an effective means of helping manage Type 1 diabetes.  
Still, much research needs to be done to fully understand the biomechanics behind 
the cells’ actions in order to expand human clinical trials.  Although complete insulin 
independence is rarely achieved in patients receiving mesenchymal stem cell 
treatment, the promising results shown so far suggest more studies be undertaken 
in hopes of finding a corrective approach to treat Type 1 diabetes.  
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INTRODUCTION 
Type 1 Diabetes Mellitus 
 Type 1 Diabetes mellitus (T1DM) is clinically associated with autoimmune 
damage to the pancreas, resulting in an inability to produce an adequate amount of 
insulin, but the root cause of the disease remains unknown.  Patients typically 
present to a physician during childhood or early adolescence with symptoms caused 
by the high blood glucose (hyperglycemic) condition such as increased thirst, 
frequent urination, increased hunger, and weight loss.  With T1DM, the body’s own 
immune system targets and destroys the insulin producing Beta-cells within the 
Islets of Langerhans in the pancreas.  The other subgroup of diabetes, Type 2 
Diabetes mellitus, results from an inability of the body to properly respond to 
already secreted insulin.  In the United States alone, over 1.25 million people are 
living with T1DM, and the prevalence of T1DM in people under the age of 20 has 
risen 20% over the last ten years37.  
 Although the complete etiology of T1DM is not understood, there is believed 
to be an interplay between both genetic and environmental factors that cause a T-
cell mediated destruction of the Beta-cells1.  Autoantibodies that target the islets 
begin to appear months to years before the symptoms and can be used as 
biomarkers for T1DM.  Individuals with particular human leukocyte antigen (HLA) 
gene complexes such as HLA-DQA1, HLA-DQB1, and HLA-DRB1 have a higher risk of 
developing islet-targeting autoantibodies. The HLA system is responsible for 
encoding the MHC proteins, whose cell-surface location plays an important 
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regulatory role in the immune system, and thus can be used to screen and study 
individuals who are at an increased risk of developing T1DM50.  The first appearance 
and the abundance of these autoantibodies, along with the progression of Beta-cell 
destruction, underlay the continuum of the pathogenesis of T1DM, seen in Figure 1.  
Staging of T1DM is particularly useful when enrolling individuals in secondary 
prevention trials that aim to reduce the impact of a disease once an individual has 
been diagnosed33.   
Figure 1. Stages of T1DM: Patients are categorized into 1 of 3 groups based on a 
variety of symptoms and physiological measures. *Beta-cell targeting 
autoantibodies may be present months to years before the onset of Beta-cell loss33. 
 3 
The appearance of the first islet-targeting autoantibody coincides with 
dendritic cells presenting the Beta-cell autoantigen and the subsequent responses of 
CD4+ helper T cells and CD8+ cytotoxic T cells to the autoantigen (Figure 2).  B cell 
exposure to these Beta-cell autoantigens leads to the production of the islet-
targeting autoantibodies, and antigen presentation by dendritic cells and other B 
cells drives the activation of Beta-cell specific T cells which attack the pancreas.  
Patients that have progressed to stage 3 T1DM have detectable levels of both CD4+ 
and CD8+ Beta-cell autoantigen specific T cells46.  Insulin secretion decreases in 
parallel with the destruction of the pancreatic Beta-cells, eventually resulting in 
hyperglycemia as glucose fails to be properly absorbed and remains in the 
bloodstream. Acute symptoms such as polydipsia, polyuria, and polyphagia develop 
rapidly.  Long-term systemic complications such as atherosclerosis, peripheral 
vascular disease, and an increased risk of infection can develop over time in 
individuals with diabetes3.  Patients are also at risk for microvascular complications 
such as retinopathy, renal disease, and neuropathy, along with macrovascular 
complications such as stroke, heart disease, and hypertension. As a result of the 
autoimmune attack on the pancreas, diabetics have an increased risk of developing 
acute and chronic pancreatitis, inflammation of the pancreas, that in turn leads to an 
increased risk of pancreatic cancer51. 
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Figure 2. Pathogenesis of T1DM: The production of islet-targeting autoantibodies 
act as biomarkers indicative of the presymptomatic stage of diabetes.  Dashed 
arrows show potential interactions between B cells and dendritic cells, and B cells 
and CD8+ T cells33. 
 
Management of T1DM primarily aims at glycemic control and the promotion 
of a healthy lifestyle in order to prevent severe hyperglycemia and ketoacidosis. To 
date, insulin therapy remains the most widely used treatment option, with the daily 
introduction of exogenous insulin dosed based on body weight, gender, blood 
glucose levels, and other considerations10.  Other less commonly used treatment 
options include amylin analogues, whole pancreas or islet transplantation, as well as 
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stem cell therapy.  None of these treatment options have proven completely 
curative, and all have flaws.  Insulin treatment requires the patient to constantly 
monitor his or her glucose levels by taking blood samples via prick and measuring 
them via a blood glucose monitoring device and then administer the proper amount 
of insulin as needed.  Amylin analogues act synergistically with insulin and is only 
given as a supplement rather than as a stand-alone treatment.  Pancreas and islet 
transplantation is limited by the number of donors and reserved only for severe 
cases of T1DM due to the requirement of lifelong immunosuppression usage 
associated with such transplants.  Still, these alternative treatments have shown the 
ability to reduce the severity of hyperglycemia and have been prime targets for 
further experimentation6.  Recent advancements have led to the ability to 
differentiate mesenchymal stem cells (MSCs) into insulin-producing cells (IPCs) in a 
laboratory environment, yet little is known about long term efficacy of such 
treatment in vivo.  With a doubling time between 48-72 hours and the capability to 
undergo more than 60 rounds of doubling, obtaining a large enough sample of MSCs 
for expanded human clinical trials is becoming readily available12. 
Mesenchymal Stem Cells   
The shortcomings mentioned in the current treatments for T1DM has led to 
the development of more novel therapeutic approaches.  The current standard for 
the treatment of T1DM, exogenous insulin injections, fails to adequately mimic the 
activity of endogenous insulin when administered over many years and requires the 
patient to maintain a strict routine for monitoring his or her own blood glucose 
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levels.  With this treatment, the damage to the Beta-cells continues to worsen as the 
autoimmune attack on the pancreas is not interfered with. As the therapeutic 
potential of stem cells has started to take hold in other fields of regenerative 
medicine, their usage in the treatment of diabetes is starting to be explored as a 
means of treating the underlying causes of diabetes rather than solely focusing on 
managing the symptoms57. 
After being administered, stem cells are able to migrate to sites of injury via a 
chemoattraction process utilizing integrin proteins, and once at the site are able to 
undergo further, more specialized, differentiation which can replace damaged 
tissues20.  These cells are classified into two groups based on their origin: embryonic 
stem cells (ESCs) or adult stem cells (ASCs).  ESCs are pluripotent and can 
differentiate into any germ line cell, however they are scarcely used in clinically due 
to the ethical controversy surrounding their harvesting process.  Instead, ASCs, 
which are multipotent, and thus can differentiate into fewer cell types than ESCs, are 
the current model of stem cell being explored for therapeutic properties.  ASCs are 
further divided into hematopoietic stem cells (HSCs) and MSCs.  MSCs have been 
noted to serve an immunosuppressive role in transplantation by inhibiting T-cell 
and B-cell proliferation, and can be genetically modified by adding the desired MHC 
complex so as to reduce the chance of an immune rejection40. 
 The usage of MSCs in diabetes treatment has been explored due to their 
capability to generate and support existing insulin producing Beta-cells within the 
pancreas, and thus they provide a novel and exciting therapeutic tool for the 
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treatment of T1DM. Initially, bone marrow derived MSCs (BM-MSC) were the most 
common source of MSCs used in the clinic, as bone marrow provides the largest 
reservoir of both MSCs and HSCs42.  Isolation of stem cells from bone marrow relies 
on the physical adherence of the cells to the plastic cell culture plate used in the 
isolation and purification process of the human bone marrow sample.  Flow 
cytometry is then used to identify specific antigen expression of CD factors that are 
expressed exclusively on MSCs, and then histology staining is used to indicate the 
MSCs are capable of proper lineage differentiation.  Due to the invasive and painful 
procedure required to collect the MSCs from the human sample, this source has 
decreased in popularity as other sources of stem cells have become more accessible 
and efficacious5. 
 Over the last decade, the usage of adipose tissue as a source of MSCs has been 
increasingly used by researchers due to its abundance of cells and easily accessible 
subcutaneous location.  In this procedure, small pieces of excised fat are washed and 
explanted to tissue culture flasks where they incubate for 3-5 days in proper 
medium.  A similar differentiation procedure as the BM-MSCs is then used to ensure 
properly functioning adipose derived mesenchymal stem cells (AD-MSCs) are 
isolated24.  
A direct comparison between AD-MSCs and BM-MSCs has revealed in 
multiple studies that AD-MSCs have greater proliferative, differentiation, and 
immunomodulatory potential.  In one such study, ischemia in mice was induced by 
ligating the femoral artery, and the animals were treated with either BM-MSCs, AD-
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MSCs, or a control.  14 days post-transplantation, the mice treated with AD-MSCs 
showed a greater proportion of perfusion in the ischemic area when compared to 
the mice treated with BM-MSCs (Figure 3A).  The skeletal muscles of the mice who 
received AD-MSCs had a lower relative area of injured tissue when compared to the 
mice receiving BM-MSCs (Figure 3B).  The greater efficacy of AD-MSCs combined 
with the simpler harvesting process than BM-MSCs have made AD-MSCs the mostly 
widely used stem cell source in regenerative medicine35. 
Figure 3. Comparison of AD-MSCs and BM-MSCs: A) The amount of ischemic 
perfusion in the ligated tissue was grater in mice that received AD-MSCs.  B) Mice 
receiving AD-MSCs showed less injured tissue 14 days post-transplantation 
compared to mice receiving BM-MSCs. *signify data that are significantly different 
from control group; # signify data that are significantly different from BM-MSC 
group35. 
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 An even more recent approach to harvesting MSCs has been via a non-
invasive mechanism by isolating them from the placenta or umbilical cord.  Stem 
cells derived in this manner have shown similar proliferative and differentiation 
abilities and an increased ability to express paracrine factors that are needed by 
insulin releasing cells when compared to BM-MSCs48.  Wharton’s jelly (umbilical 
cord matrix) is an especially abundant source of MSCs and isolation is associated 
with higher yield and comparable percentage of successful differentiation compared 
to other sources44.  The two most common methods for isolation of MSCs from 
Wharton’s jelly are shown in Figure 4.  The enzymatic method involves the usage of 
enzymes that disrupts the collagen matrix and releases cells into another solution 
that can then be centrifuged and plated on a tissue culture dish with stem cell media.  
The explant method involves direct transfer of umbilical cord tissue fragments onto 
a tissue culture dish that is filled with media that promotes the propagation of the 
stem cells44.  Nevertheless, this source of stem cells is limited by the number of 
available donors. 
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Figure 4. Enzymatic vs explant method for obtaining MSCS from Wharton’s 
jelly: MSCs are able to be obtained from the umbilical cord matrix via an enzymatic 
process that digests the tissue and leaves individual cells that can be harvested on a 
growth plate.  The explant method is a simpler process because it requires less 
manipulation of umbilical cord tissue44. 
  
 Both adipose tissue and bone marrow can provide a source of autologous 
MSCs, where the source of MSCs is from the individual himself.  The bone marrow 
isolation process yields higher numbers of MSCs when compare to adipose tissue, 
but the difficulty in recruiting donors has limited the number available for research 
purposes.  Further research has indicated that BM-MSCs may also suffer from 
contamination by HSCs, endothelial cells, and progenitor cells which may lead to a 
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heterogeneous mixture of cells.  Allogenic sources of stem cells such as Wharton’s 
jelly or umbilical cord matrix are used when the patient is too ill to have their own 
tissues isolated or when there is not enough time to allow for the expansion and 
differentiation process to occur52. 
Individuals with T1DM retain their own functional MSCs that can be 
autogenically transplanted to initiate endogenous pancreatic regeneration.  Further, 
BM-MSCs taken from Type 1 diabetic patients have shown the ability to differentiate 
into IPCs under suitable conditions55.  This would permit the patient to use his or 
her own stem cells as a source of IPCs, thus bypassing the need for a donor.  
Although feasible, chronic hyperglycemia has been shown to promote a defective 
microenvironment in diabetics that impair proper MSC functions by diminishing 
their reparative capabilities as well as reducing their migratory and proliferative 
potential14.  Thus, a healthy, third-party source of MSCs seems to be of great 
necessity for stem cell transplantation in diabetics, as MSCs play an active role in the 
healing process of damaged tissues by replacing dead cells and secreting factors that 
activate surrounding cells that enhance tissue repair55. Therefore, it has been 
theorized that MSC transplantation can be used to treat tissues impaired by chronic 
hyperglycemia by increasing Beta-cell mass.  This is accomplished via Beta-cell 
replacement through in vivo or in vitro differentiation, production of cytokines and 
other local microenvironment factors that stimulate the regeneration of endogenous 
MSCs, and reducing the autoimmunity to Beta-cells21.  
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The impressive safety record in clinical trials has made MSCs a promising 
candidate for future studies in regenerative medicine.  Donor MSCs must be 
mobilized into the peripheral target (pancreas) for the regeneration of Beta-cells.  
The goal is to provide a sufficient number of MSCs to the pancreas that might 
differentiate into islet cells and also activate endogenous stem cells by providing a 
suitable microenvironment27.  Two methods are used in the transplantation 
process: intravenous injection and direct injection.  The intravenous method is the 
most convenient method for stem cell transplants, but in diabetes, the 
intrapancreatic transplantation method is ideally used due to the higher therapeutic 
potential, with the goal of the transplanted MSCs being also to prime endogenous 
stem cells so the two lineages can jointly repair the damaged tissue39. To ensure 
homogeneity throughout the pancreas, up to ten injection sites are selected.  
Intravenous injection is used in situations when the pancreas is not easily accessible 
in the patient, as injected cells become sequestered in the lungs, therefore limiting 
the number of effective MSCs reaching the target site22.  Figure 5 provides an 
overview of the physiological consequences of MSC transplantation in diabetic 
patients. 
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Figure 5. MSC mechanisms on pancreatic disorders: The immunomodulatory 
and pro-survival properties of MSCs allow them to be used to prevent disease 
progression by protecting the pancreas and relieving disease symptoms51. 
 
Although this paper focuses on how MSCs are currently being applied in 
diabetes treatment, they are not the only type of stem cell that may possess 
applicable therapeutic benefits.  HSCs are defined by their ability to self-regenerate 
as well as differentiate into all mature blood cell types.  These include cells of the 
lymphoid lineage such as B cells, T cells, and NK cells, as well as cells of the myeloid 
lineage such as macrophages, granulocytes, megakaryocytes, and erythrocytes.  HSC 
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usage for transplantation purposes has been investigated due to the observed 
relationship between hematopoiesis and vasculogenesis.  A constant flux of HSCs 
migrating from either blood to bone marrow (homing) or from bone marrow to 
blood (mobilizing) allow for redistribution throughout the entire circulatory 
system60.  Along with providing an immediate source of progenitor cells in cases of 
blood loss or cellular damage, HSCs have been shown to contribute to the repair of 
chronically injured tissues that are nonhematopoietic in nature36.  In the face of 
selective pressure, such as damaged tissue, HSCs may be recruited in an atypical 
fashion leading the nonhematopoietic cell outcomes.  Whether this occurs by 
transdifferentiation or by cell fusion with endogenous progenitors, remains 
unknown61.  This unique property of HSCs has sparked more research into the 
biochemical mechanisms underlying this change of function, and has led a rise in the 
usage of HSCs in the field of regenerative medicine. 
The physiological potential of HSCs in treating T1DM alone warrants them a 
greater focus in explorative research.  When it was discovered that hyperglycemia 
can induce abnormal gene expression in both HSCs and their progeny, their role in 
the disease became more complicated.  Peripheral diabetic neuropathy is one of the 
major complications of chronic diabetes, damaging nerve cells and impairing the 
microvascular vessels that supply the nerves, often seen in the legs and feet.  This, in 
turn, causes a change in the microenvironment of the bone marrow.  Consequently, 
a consistent hyperglycemic environment can directly affect HSCs, leading to fusion 
of their progeny with dorsal root ganglion neurons, causing the production of TNF-
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α, a cytokine that has been implicated in the development of insulin resistance, 
along with apoptosis of the HSCs themselves.  Even in response to normoglycemic 
control or antioxidants, the pathogenesis of diabetic neuropathy does not 
completely remit and the altered bone marrow phenotype is preserved32.  Thus, the 
loss of properly functioning HSCs is a concern for diabetic patients, and treatment 
via exogenous stem cell transplantation may prevent further insulin resistance in 
Type 1 diabetics who are already struggling to produce adequate amounts of 
insulin.  
Goals 
As it is such a developing field, most of the published literature regarding the 
safety and efficacy of MSCs are from studies using animal models. The objective of 
the thesis is to provide the reader with a condensed overview of current human 
trials being undertaken that involve type 1 diabetics treated with MSCs. In doing so, 
potential highlights of the field will be illuminated while also providing an overview 
of current limitations.  MSCs have already shown regenerative capabilities in vivo, 
thus their usage in supplementing damaged islet cells has an exciting future.  Much 
has recently been discovered about the mechanism of action MSCs undertake in the 
pancreas as well as the efficacy of such treatment.  This thesis will examine the 
physiological processes that occur in vivo that make MSCs an attractive alternative 
treatment option for T1DM.  Exogenous insulin remains the gold standard 
treatment, but its popularity is not rooted in its capability to treat the disease, but 
rather in its capability in managing the disease.  This paper aims to explore how 
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MSCs may provide a therapeutic outlet that manages the underlying autoimmune 
destruction of pancreatic Beta-cells.  By providing a clear and concise overview of 
how such stem cells can produce therapeutic benefits for those with T1DM, this 
thesis can serve as a reference for patients considering a promising alternative 
treatment rather than the standard insulin doses. 
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PUBLISHED STUDIES 
Immunomodulatory Properties of MSCs 
 The capability of MSCs to escape immune recognition along with their 
immunomodulatory potential have led to their reception of great interest in 
transplantation and regenerative medicine.  When these functions were first noted, 
the exact underlying mechanisms could not be fully explained, which prompted 
further experimentation on MSCs in diabetic mice models.  Multiple in vitro and in 
vivo studies have illustrated the ability of MSCs to impair proliferative activities and 
functions of B and T cells via inhibition of cyclin expression25.  Production of soluble 
factors such as Prostaglandin E2,, and interleukin-10 arrest B and T cells in the cell 
cycle and hinder replication19.  MSCs are also capable of inhibiting differentiation, 
maturation, and function of dendritic cells, the most important antigen-presenting 
cells31.  Importantly, MSCs are not recognized by natural killer cells and can avoid 
recognition by T-cells, thus potentiating their survival in vivo49.  
 Dendritic cells are involved early on in the immune process.  They are 
derived from a CD14+ monocyte precursor, where MSCs play an important 
modulatory role.  Jiang et al investigated the effects of human MSCs on the function, 
differentiation, and maturation of monocyte derived dendritic cells in vitro.  A MSC 
culture induced with granulocyte-macrophage colony stimulating factor (GM-CSF) 
plus interleukin 4 (IL4) was shown to strongly and reversibly inhibit the initial 
differentiation of monocytes into dendritic cells. Figure 6 shows monocytes cultured 
in the presence of GM-CSF and IL-4 and monocytes treated with MSC culture.  
 18 
Mature dendritic cells treated with MSCs were shown to have reduced expression of 
CD1a, indicating a transition back to immature status31. 
 
 
Figure 6. MSCs inhibit the initial differentiation of monocytes into dendritic 
cells: (Left) Monocytes cultured with GM-CSF and IL4 resemble mature dendritic 
cells (top), whereas monocytes cultured with MSCs display macrophage-like 
morphology (bottom) when examined by phase contrast microscopy.  For the left, 
middle, and right columns for both rows: original magnifications x40, x200, and 
x1000, respectively.  (Right) CD1a and CD14 expression of monocyte-derived cells 
in MSC/monocyte cultures at differing ratios31. 
 
 When studied in vitro, it has been shown that MSCs naturally synthesize 
growth factors and cytokines that are primarily influenced by the local 
microenvironments that the MSCs are in.  Several of these trophic factors promote 
the survival of surrounding cells and also play an important role in the regulatory 
properties of the MSCs themselves2.  Thus, MSCs transplanted into the pancreas will 
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produce pro-survival cytokines that can act on the endogenous Beta-cells.  
Furthermore, MSCs have been shown to release microvesicles into the extracellular 
space through budding of the plasma membrane, which is important for cell to cell 
communication43.  Microvesicles produced by MSCs have similar surface 
characteristics (such as similar CD factors) and contain biologically active molecules 
that can be transferred to recipient cells via internalization or membrane fusion.  
Once in the target cell, microvesicles are able to alter transcription, proliferation, 
and immunoregulation, thus leading to functional changes of the target cell.  In one 
study, co culturing MSCs with microvesicles in patients with T1DM lead to an 
increase in regulatory T cell counts as well as helped induce a more immunological 
tolerant phenotype43.  For type 1 diabetics, these microvesicles may play a role in 
deterring the autoimmune Beta-cell destruction. 
To elucidate the mechanism by which MSCs modulate T cell count, 
Rasmusson et al. took a collection of cytotoxic T lymphocytes (CTL) that were 
primed and activated against stimulator lymphocytes and added MSCs to a solution.  
Both CTLs and natural killer cells function to kill pathogen-infected or neoplastic 
cells, but natural killer cells work as part of the innate immune system while CTLs 
recognize antigens, are cell-mediated, and are more specific.  The cytotoxic potential 
of the CTLs were analyzed in a chromium-release assay at various time points after 
the addition of the MSCs, and compared to a CTL culture that did not receive MSCs.  
A similar experiment was conducted with natural killer cells, where the natural 
killer cells were mixed with MSCs and the lysis was measured49.  When added at the 
 20 
beginning of the culture, the MSCs were shown to inhibit CTL-mediated lysis by 
70%, but the lysis was unaffected when in the cytotoxic phase (days 3-6).  This 
indicates that MSCs act to inhibit CTLs early in the activation process, since little to 
no cytotoxicity was reported when MSCs were added after day 349.  A later study 
revealed that MSCs appear to impair T-cell proliferation via inhibition of cyclin 
expression, which arrests T cells in the G0/G1 phase of the cell cycle28.  In addition, 
it was shown that the MSCs were able to inhibit the formation of cytotoxic 
lymphocytes when the cells were separated via a transwell system, indicating that 
the MSCs act via a soluble factor.  The MSCs were not lysed by either CTLs or natural 
killer cells, thus demonstrating their ability to escape recognition39.  Alongside 
suppression of T cells, MSCs have also been noted to suppress the proliferation of 
stimulated B cells at the same cyclin checkpoints.  Inhibition occurs in a dose-
dependent manner, but at very low dose stimulating effects were observed17. 
An immunomodulatory examination of the surface of MSCs detected an 
intermediate level of MHC class I molecules on their surface.  The expression of 
particular surface adhesion molecules such as intercellular adhesion molecule 1 and 
vascular cell adhesion molecule 1 along with a number of integrin proteins allow for 
the direct interaction with T cells38.  No MHC class II molecules or other 
costimulatory CD molecules were expressed, contributing to the cells avoidance 
from T cells.  Such suppression of T cell activity occurred regardless of the source of 
the MSCs38.  There have been supplemental studies showing that MSCs increase the 
amount of regulatory T cells while suppressing the function of other T cell 
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populations28.  All together, these properties of MSCs demonstrate their durability in 
vivo. After being transdifferentiated into IPCs and transplanted, these cells can avoid 
the autoimmune damage that plagues the endogenous Beta-cells in T1DM. 
These immunomodulatory properties of MSCs has certainly made them an 
attractive choice for research in regenerative medicine.  The first reported IPC 
generated from stem cell differentiation came in 2001 using ESCs4.  However, ESCs 
form teratomas, are surrounded by ethical controversies, and are limited in number.  
In vitro, MSCs have shown the capacity to differentiate into several cell lineages, 
including IPCs41.  When cultured under specific conditions, MSCs that have been 
precommitted to one lineage can differentiate into other cell types via a process 
known as transdifferentiation34.  These precommitted cells are able to respond to 
extracellular clues and dedifferentiate into a more primitive stem cell or are able to 
act as a cellular vehicle for the expression of the human insulin gene54.  A general 
overview of the transdifferentation process for IPCs is presented in Figure 7. 
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Figure 7. In vitro transdifferentation of IPCs from MSCs:  Schematic 
representation of the various sources of MSCs and the differentiation procedure into 
IPC for transplantation18. 
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 Two distinctive pathways exist for obtaining functional Beta-cells from MSCs: 
gene-reprogramming and factor-based transdifferentiation.  Gene-therapy involves 
the transfer a foreign gene into the MSC that activates or represses the insulin gene 
on demand.  The factor-based approach involves surrounding the MSCs in specific 
culture conditions containing extrinsic insulin-promoting factors and cytokines in 
vitro culture23.  A careful stage-wise addition and subtraction of a combination of 
extrinsic insulin-promoting factors is required for successful transdifferentiation.  
These biologically active factors are used endogenously in the endocrine pancreas 
differentiation, promote Beta-cell proliferation and differentiation, as well as 
increase insulin content of known IPCs54.  Commonly used insulin-promoting factors 
and their roles in the pancreas are summarized in Table 1.  Successfully 
differentiated MSCs are identified via an established IPC identification process.  Cells 
are selected based on their expression of particular genes associated with 
pancreatic development such as GLUT2, IslI, and glucose kinase, as well as the 
identification of C-peptide, indicating successful endogenous production of insulin.  
C-peptide is a short amino acid chain in the proinsulin molecule that gets cleaved, 
but is not present in insulin given to diabetics13.  Finally, the transdifferentiated IPCs 
are transplanted into the receiving individual18. 
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Table 1.  The role of various extrinsic factors in promoting IPC differentiation: 
A wide variety of extrinsic factors are involved in the promotion of IPC 
differentiation and insulin production18. 
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 Transplantation of MSCs has proven to be useful in slowing the progression 
of diabetes, as intravenously or intrapancreatically administered MSCs are capable 
of recovering endogenous islets as well as reverting hyperglycemia21.  The 
traditional view of stem cells would credit these therapeutic benefits to MSCs 
acquiring the phenotype of the parenchymal cells and replacing the dead cells.  Yet, 
the published studies that have examined the number of transplanted MSCs that 
functionally integrate into damaged tissue have found the levels too low to support 
such a physiological change47.  Therefore, the main contribution of MSCs in tissue 
regeneration may primarily lay in their immunomodulatory properties and ability 
to boost the function of surviving endogenous Beta-cells.  MSCs can limit T 
lymphocyte activity and stimulate regulatory T cells, as well as secrete anti-
inflammatory cytokines59.  In autoimmune animal models, administered MSCs home 
into the damaged organ and prevent the destruction of newly formed and remaining 
endogenous cells, produce trophic factors that prevent the apoptosis of remnant 
cells, and induce the proliferation and differentiation of local progenitor cells8. 
 Ezquer et al attempted to elucidate the mechanism underlying some of the 
antidiabetic effects of MSCs.   First, he attempted to assess whether transplanted 
MSCs with green fluorescent protein (GFP) differentiated into Beta-cells and/or 
modified pancreatic and systemic physiological markers of T1DM in mice.  As 
anticipated, no cells were detected that expressed both insulin and GFP in the 
recipient mice’s pancreas, indicating that administered MSCs do not differentiate in 
vivo into IPCs.  Rather, the donor MSCs were seen in secondary lymphoid organs, 
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where they inhibit the proliferation of the autoaggressive T cells by either modifying 
local cytokines or inducing more regulatory T cells.  The distribution of MSCs-GFP as 
well as presence of pancreatic cells expressing both insulin and GFP was determined 
via immunohistofluorescence and flow cytometry21.  
In addition, the abundance and functionality of regulatory and 
autoaggressive T cells was measured via flow cytometry, and both the pancreatic 
and systemic expression of both anti-inflammatory and proinflammatory markers 
along with intraislet apoptosis was recorded.  The autoaggressive T cells are 
responsible for a pro-inflammatory response, stimulating B cells to produce 
antibodies, and attacking the Beta-cells directly.  Both seven and 65 days after the 
transplantation, the mice treated with MSCs showed significantly lower amounts of 
autoaggressive T cells in both the pancreatic lymph nodes (local) and spleen 
(systemic), along with an increase in regulatory T cells in both locations.  
Proinflammatory cytokine production (when stimulated ex vivo) was lower in the 
MSC receiving mice as well22.  Comparisons between the untreated diabetic mice 
and mice receiving the MSC transplantation is presented in Figure 8. 
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Figure 8. MSCs restore the balance between regulatory and autoaggressive T 
cells: (A) The autoaggressive T cell count is highest in mice with untreated T1DM, 
and diabetic mice given MSCs were shown to have near wildtype levels systemically, 
and lower than wildtype levels in the pancreas.  (B) The amount of regulatory T cells 
is highest in mice given the MSC treatment.  
 
 
 
 
 
 
 
 28 
As with MSCs, HSCs possess the capability to engraft in the host in vivo.  
Expression of the particular homeobox gene HoxB4 confers the ability to 
functionally engraft and thus contribute to the long-term restoration of depleted 
blood lineages.  Successful expression of HoxB4 is associated with both the 
expansion of the HSC population in vivo as well as promotion of the self-renewing 
divisions of HSCs in vitro, and is needed to induce the expression of at least two 
biomarkers of definitive HSCs36.  Upstream inducers of HoxB4 as well as the 
downstream targets that allow for the acquisition of hematopoietic functions of 
HSCs remains unknown and a target for current stem cell research.  HSC 
mobilization and proliferation is often stimulated by treatment with particular 
cytotoxic drugs such as cyclophosphamide or hydroxyurea that are administered 
during the transplantation process60. 
A unique characteristic of HSCs is their lack of programmed death ligand 1 
(PD-L1), which is an important immune checkpoint in the T1DM mouse model.  PD-
L1 plays an essential role in maintaining immune tolerance by controlling and 
inhibiting activated T cells.  The cross play between the PD-L1 ligand and its 
receptor, expressed primarily on activated T cells, inhibits T cell activation and 
favors apoptosis, and thus mice deficient in PD-L1 develop diabetes at an 
accelerated rate62.  A genome-wide assay revealed that a network of microRNAs 
exist that are in control of PD-L1 expression, and that silencing of one of the key 
altered microRNAs successfully restored PD-L1 expression in HSCs.  Therefore, it 
was reasoned that restoration of the PD-L1 defect could serve as a cure for T1DM as 
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an alternative to an immunosuppressive regiment.  To do so, HSCs were genetically 
modified to overexpress PD-L1 and transplanted into a mouse model.  Results 
showed an inhibition of the autoimmune response in vivo, a reversion in the diabetic 
state in a newly hyperglycemic model, as well as homing of the HSCs to the 
pancreas.  Human patients with T1DM were shown to have the same PD-L1 
expression defect, and modified human HSCs also inhibited the immune response in 
vivo7. 
 
II. Clinical Effectiveness of MSC Therapy 
 The early 2000s provided a boom in the exploration of treatment options for 
T1DM.  Islet and pancreatic transplantations were both being tested with promising 
normoglycemic results, but a lack of donors and complicated surgery needed for the 
procedure provided road blocks to major advancements.  Concurrently, stem cell 
therapy was being explored in many fields of regenerative medicine.  Progress was 
already seen in generating cardiac cells capable of repairing heart tissues and stem 
cells were also used to replace cells damaged by chemotherapy. In 2004 the first 
experiment was done demonstrating the differentiation capabilities of MSCs into 
functional islet-like cells in an in vitro animal model.  Diabetes is induced in the mice 
via streptozotocin, a compound that is used clinically to treat pancreatic Beta-cell 
carcinoma, as streptozotocin attacks and damages Beta-cells.  After around 2 weeks 
(depending on the dose), hypoinsulinemia and hyperglycemia result in the mice due 
to insufficient Beta-cell production of insulin26. 
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 The first major breakthrough in islet cell replacement for insulin-
dependent diabetics was published in the year 2000, and was established as the 
Edmonton Protocol53.  Shapiro and co-workers performed islet transplantation in 
36 patients with T1DM in conjunction with an immunosuppressive regiment.  All 36 
patients received islet transplants from two or more donor pancreases and were 
able to quickly sustain decreased insulin dependence and had lowered need for 
exogenous insulin.  A total of 21 subjects achieved insulin independence with proper 
glycemic control at any point in the trial, with 16 of these requiring insulin again at 
2 years, and 5 remaining insulin independent.  Some subjects experienced a decline 
in renal function, and all were subject to lifelong immunosuppressant medication53.  
Despite these shortcomings, the Edmonton Protocol established a single 
transplantation method, with higher yield and greater consistency than any prior.  
Proving the efficacy of islet-cell transplantation laid the foundation for 
differentiating MSCs into IPCs for the treatment of T1DM. 
 Therapeutic benefits resulting from the usage of MSCs is quantified on four 
major criteria: fasting plasma glucose levels, C-peptide levels, glycated hemoglobin, 
and daily insulin dose.  Fasting plasma glucose measures one’s blood sugar level 
after refraining from eating for at least 8 hours, and individuals with T1DM are 
expected to have higher levels than their healthy counterparts.  Glycated 
hemoglobin refers to the hemoglobin (carrying oxygenated blood) that is chemically 
linked to glucose, and is generally higher in diabetics as a result of higher blood 
glucose levels. Daily insulin injection dose is the concentration of exogenous insulin 
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that is given each day.  Combined, these measures are used to indicate the success of 
MSC treatment13. 
 Initial experiments were done on rat models in order to determine if 
properly differentiating MSCs into IPCs could in turn lead to increased insulin 
production12.  Femoral bone marrow derived stem cells were isolated from healthy 
rats and induced to differentiate into functional pancreatic cells following 
established protocols.  A radioimmunoassay was applied on MSCs after isolation in 
order to assess insulin excretion level.  The insulin mRNA excreted from a sample of 
differentiated MSCs was compared to that from a sample of undifferentiated MSCs, 
summarized in Table 212.  To test the glucose-controlling function of these 
differentiated MSCs, six diabetic rat models were selected.  Each rat received a 
subcutaneous injection, with three rats receiving IPCs differentiated from MSCs, two 
receiving undifferentiated MSCs, and one not receiving any cells.  The individual 
blood glucose levels of each rat was compared before the injection and one week 
after treatment, summarized in Table 312.  Through these experiments, Chen and his 
laboratory were able to successfully show the differentiation capabilities of MSCs to 
IPCs that were both morphologically similar to and played a similar physiologically 
role as endogenous pancreatic islet cells when transplanted into a mammalian 
model.   
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Table 2. Insulin secretion changes in pre- and differentiated MSCS (IU/L): 
MSCs require a proper transdifferentiation protocol into islet-like cells in order to 
produce significant amounts of insulin12. 
 
 
 
 
 
 
 
 
 
 
 
Table 3.  Blood glucose levels for IPC and undifferentiated MSC treatment: Rats 
given MSCs differentiated into IPCs (Islet1, Islet2, Islet3) showed decreases in blood 
glucose levels 1 week post-transplantation, whereas rats given undifferentiated 
MSCs (MSC1, MSC2), or no treatment (non), showed no reductions in blood glucose 
levels after 1 week12. 
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 Successful transdifferentiation protocols for MSCs produce cells capable of 
expressing the insulin protein and have physical characteristics resembling that of 
endogenous Beta-cells.  Early trials saw the collection of IPCs that were functional in 
vitro, but failed to produce insulin when transplanted into a hyperglycemic model54.  
Human trials were put on hold until a proper transdifferentiation procedure that 
produced glucose-responsive IPCs in vivo was discovered.  Consequently, the usage 
of MSCs in humans with T1DM is an even newer field, with the earliest trials starting 
in 2008.  This study included only five patients, aged 14 to 28, whose blood glucose 
levels were not improving under their current insulin therapy56.  After intraportal 
transplantation of a combination of AD-MSCs derived IPCs along with HSCs, all 
patients showed a 30% to 50% decrease in insulin requirements along with a 4 to 
26-fold increase in C-peptide levels by the end of the study.  Three of the patients 
had a history of diabetic ketosis episodes, and after receiving MSC transplants, these 
episodes appeared to go away.  Throughout the five month follow up period, no 
patients experienced any unwanted side effects or required the use of any 
immunosuppression medications.   
 A similar trial involving eleven patients with T1DM receiving an intraportal 
administration of AD-MSCs that had been transdifferentiated to IPCs along with 
HSCs was published in 201058.   As with the Trivedi study56 before it, pregnant 
women and anyone experiencing serious health complications resulting from 
diabetes were excluded from the study.  A chemiluminescence assay showed that 
these cells secreted C-peptide in vivo in response to an increase in glucose 
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concentration.  Patients were followed over a much longer period of time, 23 
months.  At the end of the study, all patients showed a mean decrease in exogenous 
insulin requirements as well as a mean increase in C-peptide levels.  Further, treated 
patients on a normal diet and who performed normal physical exercise became free 
of diabetic ketoacidosis without weight gain and without any unwanted side effects, 
all without the usage of immunosuppressants.  Although these patients still failed to 
achieve full insulin independence, the safety and effectiveness of AD-MSC based 
therapy in a longer term study were achieved.   
 In another clinical study, the long-term efficacy of Wharton jelly derived-
MSCs (WJ-MSCs) was assessed in 15 patients diagnosed with T1DM over a 24-
month period30.  As with the prior studies, insulin requirements dropped and C-
peptide levels increased significantly compared to the control group.  Most notably, 
three patients had become completely insulin independent by the end of the follow-
up period.  This was the first reported case of achieving insulin independence in a 
clinical trial.  No reports of any chronic of acute side effects, including ketoacidosis, 
were noted in the MSC group, while in the control group 3 patients continued to 
experience ketoacidosis. 
 Not all clinical trials have seen such ubiquitous benefits. A prospective 
randomized clinical study in which BM-MSCs were harvested from the iliac crest 
were intravenously transplanted in 20 patients with recent-onset T1DM.  After 4 
weeks post-infusion, C-peptide levels were increased, but this was only temporary.  
One year following the transplant, there was no significant increases in C-peptide 
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levels, glycated hemoglobin levels, or changes in required insulin dose.  However, 
there were no apparent negative changes in any of these values, indicating that the 
diabetic condition did not worsen in any of the patients9. 
Recently, patients undergoing stem cell therapy have received their 
treatment in a 4 step method, summarized in Figure 913.  Initially, bone marrow is 
stimulated in vivo by colony stimulating factor, which induces the bone marrow to 
produce stem cells and release them into the bloodstream.  Concurrently, bone 
marrow is extracted and implanted into the liver.  Next, AD-MSCs (either autologous 
or allogenic) are differentiated into IPCs and implanted into the portal circulation. 
Then, a mix of MSC-derived IPCs as well as HSCs from the bone marrow are injected 
into portal circulation.  Finally, BM-MSCs are intravenously infused into the patient. 
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Figure 9. Schematic of MSC transplantation in clinical trials: 1) Autologous BM-
MSCs are transplanted in patient if applicable. 2) AD-MSCs, either autologous or 
allogenic, are differentiated into IPCs and implanted in patient. 3) AD-MSC derived 
IPCs and HSCs from bone marrow are injected into patient. 4) BM-MSCs are infused 
intravenously13. 
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 A meta-analysis of individuals with T1DM who had received stem cell 
therapy showed that a fifth of patients showed adverse effects, which is still a safer 
form of transplantation therapy than either islet or whole pancreas 
transplantation20.  However, these adverse effects should not be completely ignored.  
Most of the problems arose as a result of the administration of a high-dose of 
immunosuppressive regimen given before the transplantation.  These side effects 
were alleviated shortly after the transplantation and subsequent immune 
reconstitution occurred.  Still, lower doses of better tolerated immunosuppressive 
medications along with stronger prophylaxis against infection appears to be 
necessary to improve therapeutic outcome. 
The first clinical trial involving the use of autologous HSC transplantation for 
individuals with T1DM, with the goal of exploring potential adverse side effects and 
evaluating potential applications of such therapy, occurred in 2014.  65 individuals 
with new-onset T1DM were enrolled in the study and followed up over a 48 month 
period.  Within the first 6 months of receiving a single HSC infusion along with an 
immunosuppression therapy, 59% of patients were able to achieve insulin 
independence, with 32% of all patients remaining insulin independent by their last 
follow up.  Every subject showed signs of improved glycemic management via 
decreased glycated hemoglobin and increased C-peptide levels compared with their 
pretreatment baseline measures.  Although the immune system of the patients 
showed near complete recovery, such as leukocyte count, over half of the treated 
individuals experienced some sort of adverse effect.  A severe infection was noted in 
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3 of the individuals, with 1 subject dying as a result of sepsis and disseminated 
intravascular coagulation, a condition in which the proteins that control blood 
clotting become overactive16.  A list of all of the adverse events that the patients 
experienced during the treatment and follow up is presented in table 4. 
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Table 4. Unfavorable side effects experienced during HSC treatment: Of the 65 
patients enrolled in the D’Addio T1DM study utilizing HSCs as treatment, 34 
experienced undesired side effects.  ATG, antithymocyte globulin; CVC, central 
venous catheter; DIC, disseminated intravascular coagulation16 
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DISCUSSION 
Discussion 
 The clinical benefit of MSCs is certainly evident, not just in the field of 
diabetes, but in the entire field of regenerative medicine.  Expectations must be 
tempered, however, as stem cells cannot simply be used as a one trick fix for the 
direct replacement of dysfunctioning organs.  Instead, it is important to understand 
the physiology behind which such cells exhibit their therapeutic benefits in order to 
best apply them in the clinic.  By specifically discerning how MSCs are isolated and 
can transdifferentiate into IPCs to be transplanted into humans for glycemic control, 
scientists can better grasp how these cells work and how they can be better used to 
treat patients.  Understanding the physiological basis behind their 
immunomodulatory properties allow for more precise experiments involving MSCs 
and can lead to novel breakthroughs. 
 A key finding in these clinical studies is the apparent decrease in amount of 
exogenous insulin that is required for proper glycemic control when given a single 
transplant of insulin producing MSCs.  Yet, only a small minority of patients in all of 
these studies were able to achieve and maintain complete insulin independence by 
the end of the trial time period.  This may result from inadequate dosing procedures 
caused by lack of current data, or the need for multiple MSC transplants given at 
different time points.  To date, there have not been any experiments considering 
multiple intravenous transplants of MSCs into humans, but such data is available for 
mouse models.  In such a study, human MSC transplants were given every 2 weeks 
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for a 6-month period.  Compared to the mice receiving a single transplant, who saw 
transient decreases in blood sugar levels that lasted for around a month, the mice 
given multiple injections saw effective restoration of glucose homeostasis.  Systemic 
oxidative stress was decreased after the 7th week, and production of human insulin 
was dramatically increased and stabilized starting in the 11th week as MSCs 
engrafted and subsequently differentiated into IPCs29.  Unfortunately for individuals 
who are unresponsive to a first MSC transplantation, repeated administration has 
shown no physiological advantages28.  For those who experience improved glycemic 
control when given an initial MSC transplant, perhaps giving multiple doses over a 
duration of time could prove to be more successful in alleviating the need for a 
constant supply of exogenous insulin.   
 Perhaps a combination therapy method may be more effective than MSC 
transplantation alone.  Combination therapy has certainly proved more effective 
than monotherapy in the treatment of diseases such as chronic obstructive 
pulmonary disease, cancer, and HIV/AIDS, so it is reasonable to delve into whether 
this is a feasible option for T1DM.  A few of the studies discussed here included HSC 
transplantation concurrently with MSCs, as bone marrow derived HSCs have 
showed similar outcomes as MSCs in improving C-peptide levels and decreasing 
glycated hemoglobin levels.  Still, these data are murky and lack conclusiveness.  The 
one large study on T1DM conducted utilizing solely HSCs as the source of stem cells 
showed extremely variable results.  Even though around a third of the subjects 
achieved and maintained insulin independence by the end of the two-year study, 34 
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of the 65 of individuals experienced negative side effects.  Worse yet, one patient 
died as a result of infection by Pseudomonas aeruginosa leading to sepsis.  These 
data suggest much more research needs to be done on the efficacy and safety of HSC 
transplantation.  With diabetes disrupting the microenvironment of the bone 
marrow leading to abnormalities in endogenous HSCs, it appears valid that some 
kind of HSC replacement could be an effective means of combating some of the 
symptoms of the disease.   Since HSCs play a major role in remodeling the diabetic 
microenvironment in a pro-insulin secreting way, this would appear to greatly 
complement the MSCs effect of improving Beta-cell efficiency.  Thus, a multifactorial 
approach to T1DM may be the most suitable method to achieving long-term glucose 
independence while minimizing any sort of adverse side effects. 
 As diabetes has become more prevalent across the developing world, there 
has become an increasing need to find novel therapeutics to combat the issue rather 
than simply manage it.  This thesis focused on the advances within the field of stem 
cell transplantation, but progress is also being made in other treatment options.  As 
discussed, islet cell replacement therapy is a viable option for insulin dependent 
diabetics. 
 A California company is currently developing islet-cell replacement therapies 
that may prove capable of overcoming the need for lifelong immunosuprresants and 
glucose monitoring as well as the limited number of donor cells that riddle classical 
islet cell transplantations.  Viacyte’s PEC-Direct and PEC-Encap both transplant lab-
created human pancreatic progenitor cells into patients, where the cells are able to 
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mature into functional pancreatic islet cells that induces insulin-producing Beta-
cells in response to rising glucose levels.  These products are surgically implanted 
under the skin and incorporate an encapsulated device design that protects the cells 
from the host’s immune system.  However, the current evidence is limited to phase I 
and II human trials that evaluate the safety, as there is yet to be sufficient data about 
efficacy in humans, and the length of time that the product can safely and 
functionally remain implanted is yet to be determined.  There is also no known 
estimation about the future cost of ViaCyt’s products or what the cost to the 
consumer would be15.  Regardless, ViaCyt is taking advantage of some of the 
properties of stem cells such as immune evasion and ability to produce large 
amounts of cells in a lab using PCR in order to try and combat diabetes in a new and 
promising method.  The results of their ongoing phase I and II trials could show how 
proper ingenuity and creative modification of a current treatment option’s 
shortcomings can lead to better treatment. 
 The ability to hide cells from the host’s immune system via an encapsulation 
method is an exciting advancement in improving the transplantation process.  Usage 
of an encapsulation method with AD-MSC derived IPCs has been shown to promote 
normoglycemia in diabetic mice after 2 weeks when transplanted into the 
peritoneal cavity11.   The transplanted capsules themselves were removed after 4 
weeks, with the IPCs retaining their cellular integrity and function.  In another 
study, BM-MSCs were differentiated into IPCs and encapsulated and transplanted in 
a similar method, and a second group of diabetic mice received a transplant with 
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unencapsulated IPCs via the intraportal route45.  They demonstrated that IPCs in the 
mice that received the encapsulated transplant had greater survival than the 
unencapsulated group, and the mice had further reductions in immune response 
while having similar improvement in hyperglycemia.  Cotransplantation of MSCs 
and encapsulated MSCs showed an improvement in the oxygenation of the 
encapsulated cells due to an increase in vascularization of the pancreas, yet more 
studies need to be done before this bidimensional approach is applied in human 
therapy.  Should these studies prove successful, this would be another small step 
forward in improving the efficacy of stem cell treatment in the treatment of 
diabetes. 
 A key focus of this thesis is to highlight the inadequacy of the current 
available data on stem cell treatment and the importance of further exploration.  
This work primarily rests on the shoulders of research scientists performing 
quantitative laboratory experiments that can provide statistically significant results.  
Yet, it is not the sole responsibility of researchers to further the field.  Both doctors 
and patients should be more open to the idea of alternative therapies for T1DM 
when exogenous insulin is not adequate in managing the disease.  One of the major 
hold ups in the clinical trials discussed was patient recruitment. As stem cell 
transplantation is such a new field of medicine, it is often difficult to recruit patients 
to participate in these studies, and there is no easy way to convince them with the 
current lack of conclusive evidence.  To combat this issue, it’s important for 
physicians to be open to recommending these sorts of novel therapies and be 
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diligent in describing their potential benefits to patients.  Reminding them that their 
blood glucose levels will still be constantly monitored throughout the duration of 
the trial, and that exogenous insulin will still be given when needed could alleviate 
some of the fears that patients may have.   
 Certainly, the studies to date have demonstrated that stem cell 
transplantation can be considered a safe and effective alternative treatment for 
many individuals with T1DM.  Yet, many of the cases considered in this manuscript 
have been evaluated solely in a single study, often with low statistical power.  The 
few patients enrolled in each study, often with a relatively short follow-up time, may 
not have been enough to allow for significant statistical interpretation.  Also, there is 
great heterogeneity in the makeup of the samples between studies.  For example, 
the Carlsson study used patients who were recently diagnosed with T1DM, while the 
Vanikar and Trivedi studies included patients who had been previously diagnosed 
with T1DM for anywhere from 1 to 20 years9.  Increasing the number of trials, along 
with the number of patients in each, for a longer duration of time may allow for 
powerful conclusions to be drawn.  These shortcomings are not necessarily 
reflective of MSCs as a treatment option, but rather reflect the insufficiency of 
available published data on the topic.  Much research still needs to be done on the 
specific interactions between stem cells and endogenous islet cells, and the specific 
pathways that lead to the clinical benefits that MSCs are able to exhibit in patients.   
 The results of these studies indicate that MSCs have the potential to play a 
serious role in combating the etiology of T1DM.  Though their mechanisms of action 
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are not completely understood yet and they are not completely effective in ridding 
patients of the need for exogenous insulin, MSCs have shown the ability to alleviate 
some of the symptoms of diabetes.  Larger scale studies involving greater sample 
sizes carried out over a longer duration of time still need to be conducted.  Future 
studies should be undertaken involving HSC supplementation along with 
encapsulation methods in order to try and maximize the benefits of MSCs in vivo.  
Although promising, MSC transplantation is still far away from becoming a 
permanent cure for T1DM, and any patient considering this treatment option should 
be aware of potential side effects and remain on a constantly monitored insulin 
routine.  
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